EV71 vaccines: A milestone in the history of global vaccine development

Emerging Microbes and Infections

Volumn 3, Issue , 2014, Pages

  Lu, Shan ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENTEROVIRUS 71 VACCINE; INACTIVATED VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

CHINA; CONFLICT OF INTEREST; DECENTRALIZATION; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; ENTEROVIRUS 71; ENTEROVIRUS 71 INFECTION; ENTEROVIRUS INFECTION; FIRST IN HUMAN STUDY; FUNDING; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRODUCT DEVELOPMENT; REVIEW;

EID: 84898647988     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2014.29     Document Type: Review

References (6)

1. Li R, Liu L, Mo Z et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 2014; 370: 829-837.
2. Zhu F, Xu W, Xia J et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 2014; 370: 818-828.
3. Zhu FC, Meng FY, Li JX et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013; 381: 2024-2032.
4. Xu J, Qian Y, Wang S et al. EV71: an emerging infectious disease vaccine target in the Far East? Vaccine 2010; 28: 3516-3521.
5. Zhu FC, Zhang J, Zhang XF et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376: 895-902.
6. ChouAH,LiuCC,ChangCPet al. Pilot Scale Production of Highly Efficacious and Stable Enterovirus 71 Vaccine Candidates. PLoS One 2012; 7: e34834.